Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R.
Mizuta H, et al. Among authors: takemoto a.
Nat Commun. 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w.
Nat Commun. 2021.
PMID: 33627640
Free PMC article.